Mylan Pharmaceutical, a subsidiary of Mylan N.V. announced the launch of Velpatasvir 100 mg/ Sofosbuvir 400 mg tablets under the brand name of MyHep in India. MyHep is a prescription combination to treat chronic Hepatitis C virus (HCV) infection in adults, including all six major genotypes, revealed the company in a statement. A Velpatasvir 100 mg/Sofosbuvir 400 mg combination product is currently sold by Gilead Sciences in other markets under the brand name EPCLUSA.
Hepatitis C is a blood borne disease which is usually transmitted through unsafe needle practice, blood transfusion of unscreened blood , inadequate sterilisation of medical equipment. Apart from blood, HCV can also be transferred through bodily fluids exchanged during sexual intercourse. It is also transferred to a baby from the mother.
According to the estimate, more than 70 million people in the world are suffering from Hepatitis C infection and about 400,000 people die due to Hepatitis C related diseases.
"Chronic Hepatitis C is a significant public health burden in India. When we launched Mylan's Hepato Care division in January 2015, we did so to increase access to critical, life-saving medicines for patients with chronic HCV and other liver-related conditions," said Mylan President Rajiv Malik.
"The launch of the fixed-dose combination of MyHep All is part of this mission and will help patients adhere to their chronic HCV treatment regimen," he added.
The MyHep All launch took place after Mylan’s successful launch of MyHep LVIR (Ledipasvir/Sofosbuvir combination) in India in January last year. Mylan has the non-exclusive right to produce and distribute Velpatasvir/Sofosbuvir in nearly 100 developing countries through a license agreement from Gilead Sciences.
(With IANS Inputs)